MENU
+Compare
ALBBY
Stock ticker: OTC
AS OF
Jun 27 closing price
Price
$12.22
Change
+$0.22 (+1.83%)
Capitalization
6.54B

ALBBY stock forecast, quote, news & analysis

Alibaba Health is of one of China's leading e-commerce platform specializing in healthcare-related products, including prescription drugs, OTC drugs, traditional Chinese medicine, health foods, and so on... Show more

ALBBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for ALBBY with price predictions
Jul 03, 2025

ALBBY's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ALBBY turned positive on June 11, 2025. Looking at past instances where ALBBY's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALBBY's RSI Indicator exited the oversold zone, of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on June 09, 2025. You may want to consider a long position or call options on ALBBY as a result. In of 63 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 132 cases where ALBBY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

ALBBY moved below its 50-day moving average on June 17, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ALBBY crossed bearishly below the 50-day moving average on June 02, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALBBY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.203) is normal, around the industry mean (3.463). P/E Ratio (53.107) is within average values for comparable stocks, (181.246). Projected Growth (PEG Ratio) (1.661) is also within normal values, averaging (1.915). Dividend Yield (0.000) settles around the average of (0.050) among similar stocks. P/S Ratio (1.538) is also within normal values, averaging (0.903).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALBBY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Walgreens Boots Alliance (NASDAQ:WBA).

Industry description

The drugstore chains industry includes stores that sell medicines (both prescription and non-prescription), health, beauty and personal care products. Over time, many pharmacy retail chains have launched their own pharmacy benefits management services. Since demand for medical products is typically less sensitive to economic cycles, drugstore retail chains industry could be largely considered as non-cyclical. CVS Health Corporation, Walgreens Boots Alliance Inc. and Rite Aid Corporation are some of the biggest operators in this industry.

Market Cap

The average market capitalization across the Drugstore Chains Industry is 4.21B. The market cap for tickers in the group ranges from 3.29K to 18.71B. WBA holds the highest valuation in this group at 18.71B. The lowest valued company is RLLVF at 3.29K.

High and low price notable news

The average weekly price growth across all stocks in the Drugstore Chains Industry was 6%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was -2%. SCNX experienced the highest price growth at 48%, while PETS experienced the biggest fall at -2%.

Volume

The average weekly volume growth across all stocks in the Drugstore Chains Industry was -22%. For the same stocks of the Industry, the average monthly volume growth was 19% and the average quarterly volume growth was -54%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 69
Price Growth Rating: 58
SMR Rating: 71
Profit Risk Rating: 95
Seasonality Score: -8 (-100 ... +100)
View a ticker or compare two or three
ALBBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry DrugstoreChains

Profile
Fundamentals
Details
Industry
N/A
Address
Guanghua Road
Phone
N/A
Employees
1560
Web
https://www.alihealth.cn